Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDSA NASDAQ:GLSI NASDAQ:KROS NASDAQ:NBP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDSAEdesa Biotech$4.98+0.2%$7.08$0.72▼$20.32$49.07M1.032.10 million shs295 shsGLSIGreenwich LifeSciences$13.62+1.3%$21.63$7.78▼$34.10$199.93M1.4244,981 shs5,136 shsKROSKeros Therapeutics$10.14+0.6%$10.77$9.69▼$22.55$197.11M0.97216,125 shs163,345 shsNBPI-Mab$1.73-1.4%$1.75$1.46▼$6.79$202.97M1.45806,990 shs856 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDSAEdesa Biotech-7.10%-17.58%-39.32%-68.74%+113.30%GLSIGreenwich LifeSciences+0.07%-8.19%-32.04%-37.73%+16.45%KROSKeros Therapeutics-1.37%-4.73%-8.37%-9.28%-30.60%NBPI-Mab-1.69%-4.37%+6.71%-25.53%+174,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDSAEdesa Biotech$4.98+0.2%$7.08$0.72▼$20.32$49.07M1.032.10 million shs295 shsGLSIGreenwich LifeSciences$13.62+1.3%$21.63$7.78▼$34.10$199.93M1.4244,981 shs5,136 shsKROSKeros Therapeutics$10.14+0.6%$10.77$9.69▼$22.55$197.11M0.97216,125 shs163,345 shsNBPI-Mab$1.73-1.4%$1.75$1.46▼$6.79$202.97M1.45806,990 shs856 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDSAEdesa Biotech-7.10%-17.58%-39.32%-68.74%+113.30%GLSIGreenwich LifeSciences+0.07%-8.19%-32.04%-37.73%+16.45%KROSKeros Therapeutics-1.37%-4.73%-8.37%-9.28%-30.60%NBPI-Mab-1.69%-4.37%+6.71%-25.53%+174,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDSAEdesa Biotech 2.67Moderate Buy$5.000.38% UpsideGLSIGreenwich LifeSciences 2.33Hold$57.00318.50% UpsideKROSKeros Therapeutics 2.25Hold$20.40101.28% UpsideNBPI-Mab 2.00Hold$9.00421.74% UpsideCurrent Analyst Ratings BreakdownLatest EDSA, NBP, KROS, and GLSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026GLSIGreenwich LifeSciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $69.006/29/2026EDSAEdesa Biotech Brookline Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/24/2026EDSAEdesa Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/1/2026NBPI-Mab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026NBPI-Mab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026GLSIGreenwich LifeSciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/15/2026KROSKeros Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/4/2026NBPI-Mab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDSAEdesa BiotechN/AN/AN/AN/A$0.45 per shareN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.03 per shareN/AKROSKeros Therapeutics$244.06M0.82$4.50 per share2.25$15.51 per share0.65NBPI-Mab$3.89M51.28N/AN/A$2.00 per share0.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDSAEdesa Biotech-$7.19M-$1.34N/AN/AN/AN/A-286.52%-75.36%8/14/2026 (Estimated)GLSIGreenwich LifeSciences-$19.36M-$1.57N/AN/AN/AN/A-941.15%-368.53%8/13/2026 (Estimated)KROSKeros Therapeutics$87.01M-$3.01N/AN/AN/A-256.60%-17.04%-15.84%8/5/2026 (Estimated)NBPI-Mab-$46.27M-$0.36N/AN/AN/AN/AN/AN/AN/ALatest EDSA, NBP, KROS, and GLSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2026N/AEDSAEdesa Biotech-$0.44N/AN/AN/AN/AN/A8/13/2026Q2 2026GLSIGreenwich LifeSciences-$0.33N/AN/AN/AN/AN/A8/5/2026Q2 2026KROSKeros Therapeutics-$1.25N/AN/AN/A$0.81 millionN/A5/14/2026Q2 2026EDSAEdesa Biotech-$0.24-$0.49-$0.25-$0.49$0.05 millionN/A5/14/2026Q1 2026KROSKeros Therapeutics-$1.0229-$1.21-$0.1871-$1.21$1.93 million$0.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEDSAEdesa BiotechN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/AKROSKeros TherapeuticsN/AN/AN/AN/AN/ANBPI-MabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDSAEdesa BiotechN/A4.764.76GLSIGreenwich LifeSciencesN/A2.012.01KROSKeros TherapeuticsN/A22.6122.62NBPI-MabN/A8.098.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDSAEdesa Biotech5.50%GLSIGreenwich LifeSciences4.16%KROSKeros Therapeutics71.56%NBPI-Mab38.38%Insider OwnershipCompanyInsider OwnershipEDSAEdesa Biotech24.40%GLSIGreenwich LifeSciences51.47%KROSKeros Therapeutics12.60%NBPI-Mab22.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDSAEdesa Biotech209.63 million7.28 millionNot OptionableGLSIGreenwich LifeSciences314.68 million7.12 millionNot OptionableKROSKeros Therapeutics10019.79 million17.30 millionOptionableNBPI-Mab380115.65 million90.09 millionN/AEDSA, NBP, KROS, and GLSI HeadlinesRecent News About These CompaniesNovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026July 24, 2026 | globenewswire.comI-Mab (NASDAQ:NBP) Trading Down 4.9% – Time to Sell?July 23, 2026 | defenseworld.netDI-Mab (NASDAQ:NBP) Trading Down 4.9% - What's Next?July 23, 2026 | americanbankingnews.comI-Mab (NASDAQ:NBP) Trading Down 4.9% - Time to Sell?July 23, 2026 | marketbeat.comNovaBridge: Rebranded, Repackaged, But Far From De-RiskedJuly 6, 2026 | seekingalpha.comNovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive OfficerJune 29, 2026 | globenewswire.comNovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric CancerJune 16, 2026 | globenewswire.comCong Claire Xu Sells 3,494 Shares of I-Mab (NASDAQ:NBP) StockJune 3, 2026 | insidertrades.comNovaBridge to Present at the 2026 Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comNovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor ConferenceMay 12, 2026 | globenewswire.comMark Arnold Hagler Buys 230,000 Shares of I-Mab (NASDAQ:NBP) StockApril 29, 2026 | insidertrades.comNovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline ValueApril 22, 2026 | globenewswire.comNovaBridge's Givastomig Could Drive A Major Re-RatingApril 9, 2026 | seekingalpha.comNovaBridge Reports Full Year 2025 Financial Results and Provides Business UpdateApril 7, 2026 | globenewswire.comNovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric CancerMarch 16, 2026 | globenewswire.comNovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD StudyMarch 9, 2026 | globenewswire.comNovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026March 3, 2026 | globenewswire.comNovaBridge to Present at the Leerink Partners 2026 Global Healthcare ConferenceMarch 2, 2026 | globenewswire.comNovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech PlatformFebruary 19, 2026 | globenewswire.comNovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric CancerFebruary 17, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEDSA, NBP, KROS, and GLSI Company DescriptionsEdesa Biotech NASDAQ:EDSA$4.98 +0.01 (+0.22%) As of 09:35 AM Eastern This is a fair market value price provided by Massive. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Greenwich LifeSciences NASDAQ:GLSI$13.62 +0.17 (+1.26%) As of 09:34 AM Eastern This is a fair market value price provided by Massive. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Keros Therapeutics NASDAQ:KROS$10.14 +0.07 (+0.65%) As of 09:35 AM Eastern This is a fair market value price provided by Massive. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.I-Mab NASDAQ:NBP$1.72 -0.03 (-1.43%) As of 09:34 AM Eastern This is a fair market value price provided by Massive. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insiders Sell, Institutions Buy: The AI Trade Is Getting More Interesting D-Wave’s AT&T Deal Shows Quantum Computing Is Moving Beyond Theory Welltower at 52-Week Highs—But Analysts Believe There's More to Come These 3 Stocks Have Soared in 2026—Can They Keep Climbing? UPS Just Gave Investors a Second Chance to Buy Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction Amkor Sells Off After Earnings—Why Weak Guidance Isn't the Real Story Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
